Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA’s Califf Notes ‘Price To Pay’ For Missed Inspections During Senate COVID Funding Hearing

Jun 17 2022

• By Brenda Sandburg

COVID funding — Congress questions US FDA policies in dispute over COVID-19 emergency funding. • Source: Shutterstock

Related Content

Surprise US FDA Facility Inspections Resume In India

May 24 2022

Moderna, Pfizer Nab Unanimous Votes For Pediatric COVID Vaccines But Advisors Hint At Moderna Dosing Advantage

Jun 16 2022

US FDA May Rethink White Oak Campus As Agency Plots ‘New Normal’ For Work

Jun 03 2022

US FDA’s 2022 Novel Agent Actions Suggest Acceleration In Use Of Complete Response Letters

Mar 10 2022

Biden’s ‘Test To Treat’ Plan Will Include Merck And Pfizer COVID Pills, But Only One Gets Public Thanks

Mar 03 2022

House Appropriators Continue Pressing US FDA To Conduct Surprise In-Person Inspections

Mar 10 2022

Related Companies

Pfizer Inc.

BioNTech SE

Moderna, Inc.

Additional Topics

United States Manufacturing Coronavirus COVID-19 Leadership Politics FDA Vaccines Policy Consumer Dietary Supplements OTC Drugs Warning Letters BioPharmaceutical

More from Manufacturing

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window